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Abstract
The hallmark of type 1 diabetes (T1D) is a decline in functional β-cell mass arising as a result of 
autoimmunity. Immunomodulatory interventions at disease onset have resulted in partial 
stabilization of β-cell function, but full recovery of insulin secretion has remained elusive. Revised 
efforts have focused on disease prevention through interventions administered at earlier disease 
stages. To support this paradigm, there is a parallel effort ongoing to identify circulating 
biomarkers that have the potential to identify stress and death of the islet β-cells. Whereas no 
definitive biomarker(s) have been fully validated, several approaches hold promise that T1D can 
be reliably identified in the pre-symptomatic phase, such that either β-cell preservation or 
immunomodulatory agents might be employed in at-risk populations. This review summarizes the 
most promising protein- and nucleic acid-based biomarkers discovered to date and reviews the 
context in which they have been studied.
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Introduction
Type 1 diabetes (T1D) is characterized by the immune-mediated destruction of the insulin 
producing pancreatic β-cells. T1D arises from a break in immune tolerance and infiltration 
of auto-reactive T cells that target the β-cells, leading to loss of β-cell function and mass and 
a lifelong requirement for exogenous insulin [1]. To preserve β-cell function, a number of 
immunomodulatory drugs have been tested around the time of T1D clinical diagnosis. A 
handful of drugs, including anti-CD3, anti-CD20, CTLA4-Ig, and alefacept have led to a 
modest preservation of β-cell function [2–6]. However, true remission from T1D, as defined 
by insulin independence, remains elusive. These outcomes could be explained by the low 
proliferative and regenerative capacity of human β-cells [7, 8], combined with the possibility 
that interventions were initiated too late in disease, occurring after the time in which 
intrinsic stress pathways in β-cells have been so robustly activated that even modulation of 
autoimmunity could not prevent β-cell decline, or treating autoimmunity with the depleting/
immunomodulatory agents mentioned above does not address the coexisting β-cell 
dysfunction. This may be an equally important pathogenic abnormality that should be also 
targeted therapeutically. In recent years, data characterizing intrinsic β-cell stress in T1D 
suggest that processes such as β-cell calcium dyshomeostasis, misfolded protein 
accumulation, oxidative stress, and endoplasmic reticulum stress become activated early 
during the evolution of T1D and act to either initiate immune activation through formation 
of neoantigens or serve to augment autoimmune-mediated β-cell death and dysfunction [9–
11]. Whereas these pathways may serve as points of therapeutic intervention, focused 
methods to identify biomarkers that reflect an authentic signature of β-cell stress and/or 
death may also improve our ability to optimally time immunomodulatory and other forms of 
interventions in T1D. In such a paradigm, a valid signature of β-cell stress could serve as a 
signal to initiate immunomodulatory therapy in the pre-T1D diabetic period. Thus, 
interventions in the newly defined stages 1–2 of the pre-symptomatic phase of T1D [12] 
offer the promise of more effective preservation of β-cell mass. However, a challenge in the 
field of β-cell biomarkers is the fact that β-cells represent a very small fraction (≤1 %) [13] 
of total pancreatic mass and an even smaller fraction of total body cellular mass. 
Historically, detection of biomarkers that emanate from the β-cell has been largely outside of 
the technical capacity of most laboratories. However, with the advent of next-generation 
sequencing technologies and more sensitive/specific nucleic amplification, mass 
spectroscopic, and antibody-based methodologies, both the identification and detection of 
promising biomarkers that are β-cell specific/selective is becoming a reality. Here, we 
review the status of select protein and nucleic acid biomarkers that provide insight into the 
health of the β-cell and have the potential, alone or in combination, to identify individuals 
with T1D who may benefit from therapies aimed at preservation of insulin secretion.
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Proinsulin/C-peptide Ratio as a Circulating Biomarker of β-Cell Stress in 
T1D
The islet β-cell is a highly secretory cell that is singularly tasked with the heavy biosynthetic 
burden of insulin production. Efficient protein translation and processing requires a robust 
endoplasmic reticulum (ER). Under conditions of T1D autoimmunity and inflammatory 
stress, insulin demand may exceed the ability of the β-cell ER to process newly translated 
proteins, leading to accumulation of unfolded proteins. If this process continues without 
resolution, it will lead to activation of ER stress and pro-apoptotic signaling pathways [14]. 
A growing number of preclinical studies suggest that β-cell ER stress contributes to the 
pathogenesis of T1D, prior to the onset of hyperglycemia [15–17]. In human T1D, 
immunostaining of islets from donors with T1D revealed abnormal expression of ER stress 
markers, including C/EBP homologous protein (CHOP), activating transcription factor 6 
(ATF6), and spliced X-box binding protein 1 [15, 18].
Insulin biosynthesis begins with the production of preproinsulin at ribosomes. Preproinsulin 
is then converted to proinsulin within the ER by cleavage of the N-terminal signal peptide. 
Further processing and cleavage occurs in the ER, Golgi network, and secretory granules 
before release of mature insulin and C-peptide into the circulation [19]. A hallmark of β-cell 
ER dysfunction is the accumulation and secretion of inadequately processed proinsulin 
molecules [14]. Therefore, β-cell ER stress may be detectable in a minimally invasive 
manner via measurement of the ratio of circulating proinsulin relative to insulin or C-peptide 
[16]. Using proinsulin/C-peptide (PI/C) ratios as a non-invasive marker of β-cell dysfunction 
could provide a means to identify individuals at risk of developing T1D prior to the onset of 
massive β-cell destruction. Evaluation of this ratio may also provide a means to monitor 
disease evolution after diagnosis [20]. In considering studies that examined PI/C ratios (see 
Table 1), it is important to recognize that ELISAs for proinsulin and C-peptide have evolved 
considerably over the last several years. Current assays exhibit significantly greater 
sensitivity and specificity.
A series of studies in Northern Europe have examined PI/C ratios in family members at risk 
for T1D. Fasting PI/C ratios were inversely correlated to first phase insulin response during 
an intravenous glucose tolerance test performed on 23 antibody-positive Finnish siblings of 
persons with T1D [25]. Among siblings followed longitudinally, 7/9 who progressed to 
develop T1D had an increase in PI/C ratio during the 6 months prior to diagnosis [39]. In the 
Belgian Diabetes Registry, autoantibody-positive first-degree relatives with random PI/C 
ratios above the 66th percentile had an increased 5-year risk of T1D development [26]. Sims 
et al. recently reported that within the TrialNet Pathway to Prevention cohort, an 
international cohort of autoantibody-positive family members of individuals with T1D, 
fasting PI/C ratios were significantly increased ~12 months prior to onset of T1D [27••]. 
Elevations were most pronounced in children ≤10 years, where median PI/C ratios were 3-
fold higher than those who did not progress to T1D. However, even among the entire group, 
increased PI/C ratios were associated with increased odds of progression to T1D, after 
correction for age and BMI [27••].
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Several groups have identified on average a 3–10-fold elevation in PI/C ratios at T1D 
diagnosis compared to controls [21–23]. Although C-peptide levels are typically increased in 
the months after diagnosis, this period has still been largely associated with a concomitant 
increase in proinsulin levels, with varying patterns in PI/C ratios during this partial 
remission or honeymoon period [21–24]. PI/C ratios at diagnosis are inversely correlated 
with length of the honeymoon period [21]. Treatment of new-onset subjects with 
cyclosporine reduced PI/C ratios, with an increased percentage of subjects experiencing a 
non-insulin requiring honeymoon [22]. Data regarding PI/C ratios in longer-standing T1D is 
more limited. Among 73 Swedish pediatric subjects with T1D for >2 years, fasting 
proinsulin and C-peptide levels were highly correlated. Notably in that study, proinsulin was 
still detected in 27.8 % of subjects with a negative fasting C-peptide [40], suggesting either 
complete failure to process proinsulin in these individuals or significant differences in 
sensitivity of the assays for proinsulin and C-peptide.
Intriguingly, proinsulin/C-peptide ratios also appear to be increased in lower risk family 
members compared to controls with no family history of type 1 diabetes. Several cohorts 
have identified elevations in fasting proinsulin despite similar fasting C-peptide/insulin or 
blood glucose levels in siblings of subjects with type 1 diabetes, independent of high-risk 
HLA status [41–43]. Increased fasting proinsulin levels have also been reported in parents 
and children of individuals with type 1 diabetes [43]. Small-scale studies have shown 
elevations in fasting proinsulin, despite similar C-peptide values, in unaffected monozygotic 
twin siblings. Elevated proinsulin levels were independent of islet cell antibody positivity 
and were present >10 years after the sibling’s diabetes diagnosis [44, 45].
These findings could represent an inherited predisposition to β-cell dysfunction that could 
theoretically contribute to type 1 diabetes pathogenesis in affected families. Alternatively, 
increased ratios could reflect a history of autoimmune β-cell injury that did not progress to 
frank diabetes. Interestingly, analysis of random proinsulin/C-peptide ratios in cord blood of 
newborn siblings of affected patients showed no difference compared to controls [46]. These 
findings may point to later timing of an inherited β-cell defect versus physiologic differences 
in newborn proinsulin processing that masks familial disparities. Notwithstanding these 
questions, PI/C ratios remain likely to be an informative and useful component of T1D risk 
prediction algorithms, as well as an important biomarker of β-cell dysfunction in T1D 
treatment trials. Moreover, additional studies are needed to understand better the molecular 
mechanisms underlying these abnormalities.
Non-coding RNAs as Circulating Biomarkers of β-Cell Stress in T1D
Non-coding RNAs comprise a large group of RNA molecules that function post-
transcriptionally to regulate a host of cellular activities ranging from differentiation and 
proliferation to apoptosis. They include classes of RNAs referred to as micro RNAs 
(miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), small nucleolar 
RNAs (snoRNAs), and stable intronic sequence RNAs (sisRNAs) among others. The best 
characterized class of non-coding RNAs with respect to β-cell function and biomarker 
development is the miRNAs. MicroRNAs are small RNA molecules of 21–23 nucleotides 
that post-transcriptionally regulate gene expression through either the inhibition of mRNA 
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translation or reduction of mRNA stability [47, 48]. In unusual cases, miRNAs can also 
positively regulate gene expression [49, 50]. In humans, over 2500 miRNAs have been 
cataloged [51], and it is estimated that collectively these miRNAs regulate approximately 
60 % of protein-coding genes [52]. Whereas miRNAs are generated intracellularly and 
largely function in a cell-autonomous fashion, in recent years it has been appreciated that 
they can be selectively secreted extracellularly in microvesicles or exosomes and thereby 
transmit their regulatory functions to other cell types [53–55]. MicroRNAs have accordingly 
been regarded as potential circulating biomarkers that reflect activities of their cells of 
origin. In the context of diabetes, an emerging literature suggests that specific miRNAs or 
groups of miRNAs could serve as biomarkers of disease progression or diabetic 
complications [56–61]. The systemic stability of miRNAs relative to other RNA species 
allows for their measurement in a variety of biological fluids, including blood, urine, saliva, 
cerebrospinal fluid, milk, seminal fluid, and amniotic fluid, making them prime targets for 
biomarker discovery [62].
Because miRNAs are expressed broadly in a variety of tissues, none to date can be 
considered as exclusive to β-cells. However, several miRNAs have been proposed as 
biomarkers in individuals with T1D (see Table 1 for a summary). In-depth sequencing of 
human islets and isolated β-cells revealed >25 miRNAs that show relative enrichment in β-
cells [63]. One of the most abundant miRNAs in β-cells is miR-375. MicroRNA-375 was 
identified early in studies of the mouse-derived β-cell line MIN6, where it was demonstrated 
to inhibit glucose-stimulated insulin owing to effects on vesicle exocytosis [64]. Using 
knockout mouse models, Poy et al. showed that miR-375 was required for the maintenance 
of normal β- and α-cell mass during mouse pancreas development [65]. The relative 
abundance and functional role of this miRNA naturally led to studies of its utility to serve as 
a biomarker of β-cell stress and/or mass. Erener et al. [28] showed in mice that 
streptozotocin (STZ) treatment, which selectively destroys β-cells, results in increases in 
circulating miR-375 levels, and that the NOD mouse model of T1D exhibited elevations in 
miR-375 during the weeks prior to development of frank hyperglycemia. In the islet 
transplantation setting in humans where acute β-cell death is observed, Kanak et al. [29••] 
showed that circulating miR-375 levels were elevated immediately post-transplantation and 
remained elevated up to 7 days later. In the T1D setting, C-peptide-negative individuals 
exhibited higher circulating miR-375 levels compared to individuals with more substantial 
β-cell mass, such as non-diabetic controls, individuals with T2D, and individuals with 
maturity onset diabetes of the young (MODY) [66••]. These findings suggest that steady-
state circulating levels of miR-375 are more likely a reflection of dying β-cells rather than 
prevailing β-cell mass.
To identify other miRNAs that contribute to the pathogenesis of T1D and might serve as 
biomarkers of β-cell stress, Roggli et al. [30] performed global microarray profiling of 
human islets treated with a cocktail of proinflammatory cytokines and demonstrated 
increases in miR-21, miR-34a, and miR-146a. Notably, these same miRNAs were elevated 
in the islets of pre-diabetic NOD mice, and blockade of these miRNAs using anti-miRs 
prevented the loss in insulin secretion from MIN6 β-cells exposed to proinflammatory 
cytokines [30]. Using a different stress paradigm of T1D, Kim and colleagues recently 
demonstrated increases in miR-34a-5p, miR-21-3p, miR155-5p, miR-1290, miR663b, and 
Mirmira et al. Page 5
Curr Diab Rep. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
miR10b-3p in human islets infected with Coxsackievirus B5, and bioinformatics analysis 
identified 57 candidate type 1 diabetes risk genes predicted to be direct targets of 
Coxsackievirus B5 responsive miRNAs [32].
These findings suggested a pathogenic role of certain miRs in β-cell dysfunction in T1D, but 
still did not address whether these and other miRs might serve as circulating biomarkers 
reflecting β-cell stress. To address this possibility, Nielsen et al. [31] undertook a 
comprehensive sequencing analysis using serum of subjects with new-onset T1D. Relative to 
control subjects after adjustment for age and gender, 12 upregulated miRNAs were identified 
in the serum of new-onset T1D subjects, including miR-152, miR-30a-5p, miR-181a, 
miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a, miR-27b, miR-25, and 
miR-200a [31]. Other studies have identified additional miRNAs associated with T1D, 
emphasizing the correlation between miRNAs and T1D diagnosis and/or control [67, 68]. 
Notably, whereas some of the miRNAs have been shown to be enriched in human β-cells 
(e.g., miR21, miR24, miR29a, miR375) [63], many are not, suggesting that they may not be 
a reflection of endogenous β-cell stress. Nevertheless, miRNAs represent a potentially 
promising class of circulating nucleic acids that could serve as biomarkers of individuals at 
high-risk for T1D (Table 1), and future studies in high-risk populations are warranted.
Data on the role and potential as biomarkers of other non-coding RNAs are limited. An 
emerging class with biomarker potential is the lncRNAs. LncRNAs are defined as non-
coding RNAs of >200 nucleotides in length. Although the mechanisms of lncRNAs is not 
well understood, like miRNAs, lncRNAs appear to function in a diversity of cellular 
processes, such as development and differentiation, proliferation, and apoptosis (for a recent 
review of lncRNAs in autoimmune diseases, see [69]). According to the NONCODE 
database [70], more than 140,000 lncRNA transcripts (encoded by more than 90,000 genes) 
have been identified in humans. As such, the potential for these RNAs to serve as 
biomarkers of disease susceptibility and development is gaining traction. Based on genome-
wide association studies, several lncRNAs have been associated with T1D susceptibility 
[71–74]. To date, however, studies are limited with respect to the expression and function of 
lncRNAs in the β-cell. A recent study in mouse β-cell-derived cell lines and NOD mouse 
islets showed that lncRNAs 1-4 are strongly upregulated in response to proinflammatory 
cytokines and disease progression, respectively [75]. Carter et al. [76] showed that in 
humans, the lncRNA GAS5 was negatively correlated with the prevalence of type 2 diabetes 
in a Veteran’s Administration cohort. Thus, further studies on the potential for lncRNAs and 
other non-coding RNAs to serve as circulating biomarkers of β-cell stress is warranted.
Differentially Methylated DNA as a Biomarker of β-Cell Stress and Death
The presence of circulating, cell-free nucleic acids derived from dying cells has been 
recognized for over 60 years, and more recently the detection and quantitation of such 
nucleic acids has been used to detect apoptosis/necrosis and/or turnover of their cells of 
origin (for a review, see [77]). One particularly promising approach in biomarker 
development has been the detection of differentially methylated DNA fragments. DNA 
methylation at CpG sites occurs via the action of DNA methyltransferases in a chemical 
reaction involving cytosine and the cofactor S-adenosyl-L-methionine. In general, 
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methylation patterns at a given gene tend to be inversely correlated with activity of the gene. 
Thus, genes that are predominantly methylated at CpG dinucleotides are highly expressed, 
whereas genes that are predominantly unmethylated at these same dinucleotides tend to be 
quiescent. DNA methylation is therefore a key epigenetic component in many stably 
repressed loci (such as the inactivated X chromosome) throughout the genome and in 
specific cell types [78]. Just as importantly, dynamic changes to DNA methylation 
frequently account for malignant transformation of many cell types as a result of activation 
or inactivation of tumor-promoting or repressing genes/loci [79]. It was this link between 
DNA methylation status and tumor formation that led investigators to consider the 
possibility that circulating differentially methylated DNA fragments arising from 
transformed cells could serve as a biomarker for cancer [80].
The islet β-cell expresses multiple genes in a nearly exclusive manner, which accordingly 
have the potential to be regulated by selective DNA methylation. Perhaps the most abundant 
and exclusive gene is the one encoding preproinsulin (INS in humans and Ins1 and Ins2 in 
mice). Relative to multiple other cell types, the human and mouse genes have been shown to 
be hypomethylated in islets and β-cells at selective CpG sites in the promoter and coding 
regions [33, 35, 81], and human INS expression is inversely correlated with methylation at 
many of these sites in human islets [82]. As with cancer cells, the concept that cell-free, 
hypomethylated INS (or mouse Ins1/Ins2) appearing in the circulation might reflect an 
increase in β-cell death or turnover was first tested in early studies of Akirav et al. [35] using 
a SYBR Green dye-based methylation-specific PCR assay against a CpG site appearing in 
the coding region of the Ins1 gene (at position +177 relative to the transcriptional start site). 
This study heralded the first generation of methylation-specific PCR assays in the T1D field, 
and involved a nested PCR approach, wherein isolated DNA from serum or plasma was 
subjected to bisulfite conversion, followed by a methylation insensitive PCR amplification 
step, manual extraction of the PCR product from a gel, followed by a methylation-specific 
PCR second step. The study by Akirav et al. [35] revealed that increases in circulating 
unmethylated mouse Ins1 DNA (relative to the methylated counterpart) were detectable 
following STZ treatment of mice and in NOD mice prior to the onset of diabetes. Since the 
description of this first study, a subsequent study by Husseiny et al. [83] described the use of 
a similar SYBR Green-based assay for the mouse Ins2 gene [83]. Other studies applied the 
assay to the analysis of human serum/plasma, showing that unmethylated INS (relative to 
methylated INS at the same CpG site) was increased at the time of T1D diagnosis [84] and 
following allogeneic islet transplantation [33]. Collectively, these studies provided the first 
evidence that β-cell-derived, unmethylated INS DNA correlates with the occurrence of 
clinical states where β-cell death is known to occur (see Table 1 for a summary of these 
studies).
The first generation assays were largely limited by the nature of SYBR Green-based 
methodologies, which included potential off-target annealing of methylation-specific 
primers, limited sensitivity that frequently required nested PCR strategies, and the 
requirement to perform separate PCRs for methylated and unmethylated target sequences. 
Fisher et al. [85] introduced a dual probe-based strategy (TaqMan), which allowed for the 
multiplex detection of both unmethylated and methylated Ins2 DNA fragments (at position 
−182 bp relative to the transcriptional start site) in sera of mouse models of T1D, with low 
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background signals and without the need for nested PCR. Use of this dual probe-based 
technology signaled the development of second generation assays that engage droplet digital 
PCR (ddPCR), a technique that involves a microfluidics approach to generate thousands of 
droplets that undergo thermal cycling and utilizes Poisson statistics to obtain absolute copy 
numbers of DNA fragments [36••, 86]. Using ddPCR and a probe that simultaneously 
detects two methylation-sensitive sites of the human INS gene (at positions +396 and +399 
relative to the transcriptional start site), Herold and colleagues [37••] showed that individuals 
at risk for T1D (autoantibody-positive individuals) who later progressed to T1D in the 
TrialNet Pathway to Prevention study collectively (averaged over several visits) had a 
statistically higher ratio of unmethylated/methylated INS DNA compared to healthy control 
subjects.
In a separate study utilizing ddPCR, Fisher et al. [36••] developed an assay targeting a single 
methylation-sensitive site at position −69 bp relative to the INS transcriptional start site, and 
showed that pediatric subjects with new-onset T1D (within 48 h of diagnosis) had higher 
absolute levels of both methylated and unmethylated insulin DNA compared to age-, 
gender-, and weight-matched non-diabetic controls. At 8 weeks post-diagnosis, the same 
individuals exhibited reductions in unmethylated INS DNA (to levels comparable to 
controls), but had persistent elevations in the methylated INS DNA levels. At 1 year post-
diagnosis, both INS DNA species were at levels comparable to controls. These findings 
point to an important distinction between the ddPCR assays of Herold et al. [37••] and 
Fisher et al. [36••]. The former group uses ratios of unmethylated/methylated INS DNA 
levels, the latter examined absolute levels of each species separately. Whereas the 
unmethylated INS DNA is thought to arise predominantly from dying β-cells, the source of 
the elevated methylated INS remains unclear. Notably, Yang et al. [82] demonstrated that 
islets from subjects with type 2 diabetes showed greater methylation at several CpG sites 
compared to islets from control subjects, suggesting that β-cells might exhibit increasing 
methylation of the INS gene with progression of disease states. In agreement with this 
observation, a recent report by the Herold group [87•] showed that the methylation status of 
the Ins1/Ins2 gene in the β-cell becomes more methylated with disease progression in the 
NOD mouse.
Because some non-β-cell types show low, but measurable frequency of unmethylated CpG 
sites in the INS gene [34••, 81], the aforementioned studies cannot rule out the possibility 
that the signals corresponding to unmethylated INS DNA might be arising (in part) from 
non-β-cells. To address this concern, the studies of Lehmann-Werman et al. [34••] used next-
generation sequencing methods to simultaneously detect methylation at six distinct CpG 
sites in the INS promoter to achieve very high specificity (since all six sites are 
simultaneously unmethylated in fewer than 0.01 % of DNA molecules arising from non-β-
cells). Using this approach, these authors showed that they were able to distinguish subjects 
with recent-onset T1D from healthy controls in a small cohort with 100 % sensitivity and 
specificity. As noted above, however, further studies will be needed in larger cohorts to 
know whether dynamic methylation at CpG sites in the INS gene with disease progression 
might limit the sensitivity of this sequencing-based approach.
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To date, most studies employing differentially methylated DNA-based biomarker assays 
have focused on the INS gene, primarily due to the specific expression of the gene in β-cells. 
The potential for other β-cell-specific genes (e.g., IAPP) was recently demonstrated [38]. 
With emerging data on whole genome methylation sequencing, it should be possible to 
identify new, perhaps more specific, methylated and unmethylated CpGs in β-cells in an 
unbiased manner without consideration of gene expression patterns.
Conclusions and Future Directions
The identification of robust panels of β-cell-specific biomarkers is a field still in its infancy. 
Nevertheless, the observations on PI/C ratios and unmethylated INS DNA in at-risk cohorts 
[27••, 37••] are suggestive of the potential for these and other biomarkers to identify 
populations of subjects who are more likely to develop T1D. Hurdles that remain include (a) 
persistent issues regarding sensitivity and specificity of biomarkers that reflect both the need 
to identify very low-level β-cell stress/death and to ensure that the signals are emanating 
from β-cells and not other uninvolved cell types, and (b) miniaturization and standardization 
of assays such that minimal blood volumes are required and that assays can be performed in 
multiple laboratories, (c) biomarker half-life considerations as β stress/death may be cyclical 
during stages 1 and 2, and (d) careful consideration of the heterogeneity of T1D with the 
acknowledgement that important differences in disease progression are driven by age and 
underlying genetic risk. Some of these hurdles, particularly specificity, can be overcome by 
utilizing a panel of biomarkers that collectively can be used to derive a score for β-cell 
health. Additionally, given the growth of “omics” data, the possibility that other as yet 
unidentified proteins (e.g., proteins emanating from alternatively spliced mRNAs) and 
molecular species (e.g., lipid and metabolite species) uniquely emanating from β-cells 
during the process of T1D development has yet to be explored.
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Table 1
Potential biomarkers of β-cell stress and death in type 1 diabetes
Potential biomarker
Data from ex vivo or 
preclinical T1D models Human data
Proinsulin/C-peptide (PI/C) Ratio Proinsulin/insulin ratios were 
increased in pre-diabetic and 
diabetic NOD mice [16].
1 PI/C ratios were increased in recent-
onset T1D and reductions in the PI/C 
ratio were associated with T1D 
remission [21–24].
2 PI/C ratios were increased in 
autoantibody-positive individuals who 
progressed to T1D [25, 26, 27••].
3 Elevated PI/C ratios were found to be 
predictive of T1D onset [27••].
miR-375 Increased in plasma of 
streptozotocin-treated and pre-
diabetic NOD mice [28].
Elevated in sera after allogeneic and autologous islet 
transplantation [29••].
miR-21, miR-34a, and miR-146a Increased in human islets treated 
with proinflammatory cytokines 
and in islets of pre-diabetic 
NOD mice [30].
miR-152, miR-30a-5p, miR-181a, 
miR-24, miR-148a, miR-210, miR-27a, 
miR-29a, miR-26a, miR-27b, miR-25, 
and miR-200a
Increased in sera of humans with recent-onset T1D [31].
miR-34a-5p, miR-21-3p, miR155-5p, 
miR-1290, miR663b, miR10b-3p
Increased in human islets 
infected with Coxsackievirus B5 
[32].
Unmethylated INS DNA 1 Increased in humans undergoing 
allogeneic islet transplantation [33, 
34••].
2 Increased in recent-onset T1D [34••, 35, 
36••].
3 Increased in high-risk autoantibody-
positive individuals prior to the onset of 
T1D [37••].
Unmethylated IAPP DNA Increased in sera of pre-diabetic 
and diabetic NOD mice [38].
Increased in recent-onset T1D [38].
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